It's quid pro quo discussions. Sorry if it's hard for you to follow. I don't just form one opinion and stick to it at all cost. Data changes it. And their cryptic press releases leave many up for review. The Company came out and cleared up enrollment number this week. Had it been in the 200s, there was a high likelihood that this trial was screen halted over something not as bullish related as suggested here. I looked for all screening, protocol, and safety in the event enrollment was not complete. I also looked at things in the event that it was, and an IA submission or Fast Track were the top of my bullish list at the time. I don't rule out anything until it can be ruled out. But, as far as my views on AA, I haven't reviewed Flips argument for it. I must admit it didn't see likely last weekend if enrollment was not complete. I also don't think it can be done without un-blinding data. But I also haven't reviewed regulatory changes that may have changed that over the last few years. EAMS only is an option to pursue if enrollment is complete as manufacturing can't support. If not, then yes, the temporary screen halt could have to do with screening. I have many perspectives on that. You can veto and stick to one though, it doesn't matter to me.
Good luck.
Market Data 
Markets 
AI
